Our peptides

Buy Peptides in UAE: Legal Framework & Suppliers 2026

Buying peptides in the UAE in 2026 means navigating three distinct legal tiers: MoHAP/EDE-registered prescription medicines (Semaglutide, Tirzepatide), DHA-licensed compounded preparations, and research-grade peptides (BPC-157, Retatrutide) that carry no approved-medicine status under UAE law. The Emirates Drug Establishment (EDE), created by Federal Decree-Law No. 38 of 2024 and operational from 2 January 2025, now holds primary regulatory authority over all medical products previously overseen by MoHAP, consolidating 44 core services under one body. Your legal exposure differs sharply depending on which tier the peptide you intend to purchase falls into. Most buyers discover that distinction only after a shipment is detained.

This article explains the three-tier framework, identifies which peptides occupy each tier, and walks through the correct ordering process for each regulatory classification. By the end, you will know how to identify a peptide's legal status, evaluate supplier credibility against six criteria, and choose between supervised clinical access and self-directed research protocols.

What Are Research Peptides? A Plain-Language Definition

A research peptide is a short chain of amino acids, typically between 2 and 50 residues, synthesised for use in scientific investigation of biological pathways, receptor activity, and metabolic signalling. These compounds are supplied without the clinical-trial data package, manufacturing controls, or regulatory authorisation required of a licensed medicine.

The "for research use only" label is not marketing language. It is a legal declaration that the compound has not been evaluated for safety or efficacy in humans by any national medicines authority, and that the supplier is not authorised to make therapeutic claims. In the UAE context, that label places the product outside the registered-medicine pathway governed by the EDE under Federal Decree-Law No. 38 of 2024, and outside the DHA-licensed compounding framework. Importing or possessing a compound labelled "research use only" with the intent to administer it therapeutically creates legal exposure that the label itself does not neutralise.

The same active molecule can exist simultaneously in both tiers. Semaglutide, for instance, is a 31-residue GLP-1 receptor agonist registered as a prescription medicine under EDE oversight, yet research-grade semaglutide such as HD Labs Semaglutide 10 mg is also available from specialist suppliers without that registration status. Tirzepatide follows the same pattern. BPC-157, a 15-residue synthetic peptide derived from a gastric protein sequence, has no approved-medicine equivalent in any major regulatory jurisdiction as of 2026; it exists only as a research-grade compound. Retatrutide, Eli Lilly's triple GLP-1/GIP/glucagon agonist, remains a pipeline drug candidate with no FDA, EMA, or EDE marketing authorisation confirmed as of mid-2026, placing it in the research tier regardless of its clinical-trial profile.

Pharmaceutical-grade differs from research-grade on four measurable axes: sterility testing, endotoxin limits, certificate of analysis traceability, and the regulatory audit trail behind manufacturing. Research-grade peptides may meet high purity thresholds, often ≥98% by HPLC (High-Performance Liquid Chromatography), but that figure alone does not confer pharmaceutical-grade or medicine status under UAE law.

The UAE Three-Tier Peptide Access Framework (2026)

Under UAE law, every peptide a buyer can access falls into one of three distinct regulatory tiers: a MoHAP/EDE-registered prescription medicine, a DHA-licensed compounded preparation, or a research-grade compound sold outside the medicines framework. Identifying which tier applies to a specific peptide determines the documentation required, the legal channel through which it can be obtained, and the buyer's exposure if that channel is bypassed.

The framework below is grounded in Federal Law No. 4 of 1983 on the Practice of Human Medicine and Federal Decree-Law No. 38 of 2024, which established the EDE and transferred core drug regulatory functions from MoHAP effective 2 January 2025. Any amendments to Law No. 4 of 1983 that post-date this article should be verified against the UAE Official Gazette or the EDE regulatory register at time of reading.

<table> <thead> <tr> <th>Tier</th> <th>Example Peptides</th> <th>Buyer Requirement</th> <th>Legal Exposure</th> </tr> </thead> <tbody> <tr> <td><strong>Tier 1, MoHAP/EDE-Registered Prescription Medicine</strong></td> <td>Semaglutide (Ozempic, Wegovy), Tirzepatide (Mounjaro)</td> <td>Valid UAE prescription issued by a licensed practitioner; dispensed by a MoHAP/EDE-licensed pharmacy</td> <td>High. Purchasing, importing, or possessing without a valid prescription breaches the medicines framework under Federal Law No. 4 of 1983</td> </tr> <tr> <td><strong>Tier 2, DHA-Licensed Compounded Preparation</strong></td> <td>BPC-157 (compounded), Tesamorelin, KPV, Ipamorelin</td> <td>Prescription from a DHA-licensed clinic; preparation by a DHA-licensed pharmacy holding compounding authorisation</td> <td>Moderate. Obtaining a compounded peptide from an unlicensed compounder, or without a prescription, removes the legal protection the compounding framework provides</td> </tr> <tr> <td><strong>Tier 3, Research-Grade Compound</strong></td> <td><a href="https://jcsg.org/ae/peptides/retatrutide/">Retatrutide</a>, Selank, Epithalon, research-format BPC-157</td> <td>None currently mandated for purchase; no prescription requirement exists because these compounds are not registered medicines</td> <td>Grey area. These peptides are not explicitly scheduled controlled substances in most cases, but import quantity and declared use can trigger UAE Customs scrutiny and potential EDE classification review</td> </tr> </tbody> </table>

Tier 1: Registered Prescription Medicines

Semaglutide is a registered prescription medicine under EDE oversight in the UAE. Tirzepatide (Mounjaro) carries the same status, consistent with its approvals by the FDA and EMA for type 2 diabetes and obesity management. Both require a valid UAE prescription and must be dispensed through a licensed pharmacy. The EDE's registered medical product directory, searchable via the MoHAP portal, is the authoritative source for confirming current registration status of any brand-name GLP-1 product. Research-grade semaglutide such as HD Labs Semaglutide 10 mg is available from specialist suppliers without that registration status, but the molecule's Tier 1 classification does not change based on the supplier's label.

Tier 2: DHA-Licensed Compounded Preparations

Compounding in Dubai operates under DHA-licensed pharmacies that hold authorisation for pharmaceutical compounding services, rather than under a separate compounding-only establishment licence. The precise licence category applicable to specific peptides such as BPC-157 or Tesamorelin is not confirmed in publicly available DHA materials and should be verified directly with the DHA before any clinical arrangement is made. Tesamorelin holds approved-medicine status in other jurisdictions (notably FDA approval for HIV-associated lipodystrophy), which means any UAE compounding of it would likely require a special-access or investigational route beyond routine pharmacy compounding. Buyers accessing Tier 2 peptides through a DHA-licensed clinic and licensed compounder carry moderate legal exposure; those who source the same compounds from unlicensed channels carry the same exposure as an unregistered medicine purchase.

Tier 3: Research-Grade Compounds

Retatrutide holds no confirmed marketing authorisation from the FDA, EMA, or EDE as of mid-2026, placing it in Tier 3 regardless of its clinical-trial profile. Selank and Epithalon similarly have no approved-medicine equivalent in any major regulatory jurisdiction. The absence of a prescription requirement for Tier 3 compounds does not mean import is unrestricted. UAE Customs may classify peptide consignments under Chapter 29 or Chapter 35 of the Harmonised System depending on declared use and product form, and EDE guidance makes clear that products with therapeutic claims must follow the medicine registration pathway regardless of how they are labelled. No specific quantity or declared-value threshold triggering mandatory MoHAP/EDE import approval for personal-use research peptides is confirmed in current public sources; treat any numeric threshold you encounter as unverified until confirmed with the Federal Customs Authority.

GLP-1 Peptides in the UAE: Semaglutide, Tirzepatide & Retatrutide

The GLP-1 agonist class splits across two regulatory tiers in the UAE: branded, MoHAP/EDE-registered medicines that require a prescription, and research-format versions of the same active compounds that carry no prescription pathway and sit in Tier 3. Which format you are purchasing determines your legal exposure before any order is placed.

Semaglutide

Semaglutide is a GLP-1 receptor agonist registered in the UAE as a prescription medicine under two brand names: Ozempic (type 2 diabetes management) and Wegovy (chronic weight management). Both require a valid prescription issued by a licensed UAE clinician and must be dispensed through a licensed pharmacy. EDE assumed responsibility for drug regulatory services from MoHAP on 2 January 2025 under Federal Decree-Law No. 38 of 2024 and now holds oversight of both registrations.

Research-format semaglutide such as HD Labs Semaglutide 10 mg is sold by international research-peptide suppliers as a lyophilised powder for laboratory use, not as a licensed medicine. Because the active compound is identical to a registered prescription drug, any research-format semaglutide imported into the UAE with therapeutic intent falls under the medicine registration pathway regardless of how it is labelled. Buyers treating it as a Tier 3 research compound carry the same legal exposure as an unregistered medicine purchase if therapeutic use is implied or demonstrated.

Tirzepatide

Tirzepatide, a dual GLP-1/GIP receptor agonist, is registered in the UAE as Mounjaro and classified as a prescription medicine under EDE oversight. The same prescription and licensed-pharmacy requirements that apply to semaglutide apply here. Research-format tirzepatide, for example HD Labs Tirzepatide 30 mg, is available from research-peptide suppliers and occupies Tier 3 by the same logic: the active compound has an approved-medicine equivalent, so therapeutic-use framing triggers the registration pathway.

A combined tirzepatide-semaglutide preparation, sometimes listed as Tirsema, has no approved-medicine equivalent in any jurisdiction as of mid-2026. It is a Tier 3 research compound with no prescription route available in the UAE.

Retatrutide

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly. As of mid-2026, it has not received marketing authorisation from the FDA, EMA, or EDE, placing it in Tier 3. Eli Lilly's Phase 3 programme was ongoing as of 2024, with no approval announcement visible in accessible regulatory or company sources through mid-2026. The Retatrutide research peptide is therefore available only through research-peptide suppliers, with no licensed clinical or compounding route in the UAE at this time.

CagriSema

CagriSema, Novo Nordisk's co-formulation of cagrilintide and semaglutide, was in Phase 3 trials as of 2024 and has no confirmed marketing authorisation from any major regulator as of mid-2026. It is an investigational compound sitting in Tier 3. No MoHAP or EDE registration entry for CagriSema is confirmed in current public sources.

The pattern across this entire class is consistent: where a branded, EDE-registered prescription medicine exists, the research-format equivalent of the same active compound does not escape the medicine registration framework simply by being sold as a powder or labelled for laboratory use. EDE guidance is explicit that therapeutic claims, not product form alone, determine which regulatory pathway applies.

Recovery & Repair Peptides: BPC-157, TB-500 & Blends

BPC-157 (Body Protection Compound) is a synthetic pentadecapeptide derived from a gastric juice protein sequence, with no approved-medicine status in any regulatory jurisdiction as of mid-2026. That single fact determines everything about how it can be legally accessed in the UAE.

BPC-157: Tier 2 or Tier 3 Depending on Source

Because BPC-157 carries no marketing authorisation from the FDA, EMA, or EDE, it cannot be dispensed as a registered prescription medicine. Two access routes remain. The first is a DHA-licensed compounding pharmacy operating under a pharmaceutical compounding authorisation, Tier 2 access, requiring a valid prescription from a licensed UAE clinician. CureCell.ae, a Dubai-based compounding pharmacy, listed BPC-157 as a compounded preparation in 2025–2026; if that listing is active and the pharmacy holds the relevant DHA compounding authorisation, this is the highest-compliance route available for BPC-157 in the UAE. The second route is purchasing a research-grade vial from a Tier 3 supplier, which carries no prescription requirement but also no clinical oversight or dispensing pharmacist review.

The Body Pharm BPC-157 5 mg compounded preparation illustrates the Tier 3 product format: lyophilised powder, labelled for research use, sold without a prescription. Buyers choosing this route should understand that the absence of a prescription does not place the product outside UAE medicines law if it is acquired or used with therapeutic intent, given EDE guidance that therapeutic claims, not product form, determine regulatory classification.

TB-500 and Combination Formats

TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide involved in actin regulation and tissue repair. Like BPC-157, it holds no approved-medicine status in any jurisdiction as of mid-2026, placing it in Tier 2 if sourced through a DHA-licensed compounding pharmacy with a prescription, or Tier 3 if purchased as a research-grade product. Body Pharm's TB-500 10 mg vial is a representative Tier 3 example available to UAE-based buyers.

Pre-blended BPC-157 and TB-500 combination pens, marketed under various brand names, sit exclusively in Tier 3. No DHA-licensed compounding pharmacy has been confirmed in public sources as offering a standardised combination format of both peptides in a single preparation. The combination format also complicates any future Tier 2 route, since compounding regulations generally require individual clinical justification for each active ingredient in a preparation.

Growth Hormone Axis Peptides: HGH, Ipamorelin & Tesamorelin

The GH-axis cluster spans the widest regulatory range of any peptide category available to UAE buyers in 2026: one compound sits in Tier 1 as a registered prescription medicine, one occupies an ambiguous Tier 2/3 position, and the remainder are unambiguously Tier 3 research-grade products.

Somatropin (Recombinant HGH)

Somatropin is a MoHAP/EDE-registered prescription medicine in the UAE, placing it in Tier 1. Legitimate access requires a valid prescription from a licensed UAE physician and dispensing through a licensed pharmacy. Body Pharm's Somatropin 100 IU Kit and Pen are sold under a research-use label, which places those specific products in Tier 3 regardless of the active substance's Tier 1 status elsewhere. Acquiring the registered prescription form without a prescription, or importing unregistered somatropin preparations, carries the same legal exposure as any unregistered medicine under Federal Decree-Law No. 38 of 2024 and the EDE's classification framework.

Tesamorelin

Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue approved in some jurisdictions, including the United States, where it is marketed as Egrifta for HIV-associated lipodystrophy. No publicly accessible MoHAP or EDE product directory entry confirms UAE registration of Egrifta or any tesamorelin-containing product as of mid-2026. Without confirmed UAE registration, tesamorelin sits in Tier 2 if a DHA-licensed pharmacy with compounding authorisation prepares it against a valid prescription, or in Tier 3 if purchased as a research product. The DHA licence category required for compounding a GHRH analogue is not specified in any publicly available DHA document, so verify directly with any clinic or pharmacy before assuming a compounded tesamorelin preparation is lawfully dispensed. Body Pharm's Tesamorelin 10 mg vial is a representative Tier 3 format.

Ipamorelin

Ipamorelin is a selective growth hormone secretagogue with no approved-medicine status in any major jurisdiction as of mid-2026, placing it squarely in Tier 3. Body Pharm's Ipamorelin 5 mg lyophilised vial is the standard research-grade format available to UAE-based buyers. EDE classification guidance makes clear that therapeutic intent, not product labelling, determines regulatory treatment, so research-labelled ipamorelin used clinically falls under medicines law.

IGF-1 LR3 and MOTS-C

IGF-1 LR3 is a long-acting analogue of insulin-like growth factor 1 with no approved-medicine status globally as of 2026. Body Pharm's IGF-1 LR3 100 mcg vial is a Tier 3 product. MOTS-C is a mitochondria-derived peptide studied for metabolic and longevity applications; it likewise holds no approved-medicine status, and the Body Pharm MOTS-C 32 Pen is a Tier 3 research preparation. Both compounds sit outside any current DHA compounding pathway given the absence of clinical indication data sufficient to support a Tier 2 prescription route.

What Is Pharmaceutical-Grade Purity? HPLC & CoA Explained

A peptide's purity percentage is only as credible as the analytical method and laboratory behind it. High-Performance Liquid Chromatography (HPLC) is the industry-standard technique: the instrument separates a dissolved peptide sample by molecular interaction with a stationary phase, then quantifies each component by the area under its chromatographic peak. A result of ≥99% purity by HPLC means that the target peptide accounts for at least 99% of the total peak area, leaving ≤1% attributable to impurities such as truncated sequences, oxidised variants, or residual solvents.

What HPLC Purity Actually Measures

HPLC area-percentage purity is not the same as absolute mass purity. The method detects UV-absorbing species; compounds that absorb weakly at the detection wavelength may be under-represented in the chromatogram. This is why a rigorous Certificate of Analysis (CoA) pairs HPLC data with mass spectrometry (MS) confirmation, which verifies that the dominant peak corresponds to the correct molecular weight of the stated peptide. Without MS confirmation, a ≥99% HPLC figure cannot rule out a co-eluting impurity of similar molecular size.

Reading a Certificate of Analysis

A Certificate of Analysis from an ISO 17025-accredited laboratory ties a purity claim to a specific manufactured batch. ISO 17025 is the international standard for testing and calibration laboratories, administered through the ILAC (International Laboratory Accreditation Cooperation) framework; accreditation means an independent body has verified the lab's competence and measurement traceability.

A CoA worth trusting contains all of the following:

• Batch or lot number, links the certificate to a discrete production run, not a generic product line
• Test date, purity degrades over time; a certificate dated more than 12 months before purchase is of limited value for lyophilised peptides stored outside validated conditions
• HPLC chromatogram, the actual graphical output, not just a summary figure; the chromatogram lets a trained reader assess peak shape and baseline noise
• Mass spectrometry result, confirms molecular identity alongside purity
• Accreditation number and scope, the lab's ISO 17025 accreditation number should be verifiable against the issuing body's public register

Supplier purity claims of ≥99% are only meaningful when backed by a batch-specific CoA from an independent ISO 17025-certified laboratory. An in-house certificate, where the manufacturer tests its own product without third-party oversight, provides no independent verification and should not be treated as equivalent.

How to Evaluate Supplier CoA Claims in the UAE

Several peptide vendors appearing on UAE search results, including emiratespeptides.com and aepeptides.ae, advertise ≥99% purity. These are unverified supplier claims as of mid-2026; neither site's CoA documentation has been independently audited for this article. Before purchasing, request the batch-specific CoA for the exact vial lot you intend to receive, confirm the issuing laboratory's ISO 17025 accreditation number, and cross-reference that number against the ILAC MRA signatory database.

This standard applies regardless of regulatory tier. A Retatrutide research peptide sold as a Tier 3 compound and an HD Labs Semaglutide 10 mg vial positioned closer to clinical use both require the same CoA scrutiny. Regulatory classification does not substitute for analytical verification of what is actually in the vial.

How to Order Peptides Online in the UAE: A Step-by-Step Guide

Ordering peptides online in the UAE follows a different path depending on which regulatory tier the compound occupies, and selecting the wrong route carries real legal and safety consequences. The six steps below map the process from tier identification through to correct storage on receipt.

Step 1: Identify the Regulatory Tier

Before placing any order, confirm whether your peptide is a MoHAP/EDE-registered medicine (Tier 1), a DHA-licensed compounded preparation (Tier 2), or a research-grade compound (Tier 3). The tier table earlier in this article covers the major peptides by name. Getting this wrong at step one invalidates every subsequent decision.

Step 2: Tier 1, Prescription and Registered Pharmacy

Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro) are regulated as prescription medicines under the Emirates Drug Establishment following Federal Decree-Law No. 38 of 2024. Obtain a valid prescription from a UAE-licensed practitioner, then dispense through a MoHAP-registered pharmacy. Purchasing these compounds from an online vendor bypassing this pathway is non-compliant regardless of the vendor's marketing claims.

Step 3: Tier 2, Compounding Clinic Consultation

For compounded peptide preparations, the access point is a DHA-licensed clinic or pharmacy authorised to provide compounding services. DarDoc.com has appeared in UAE search results advertising home-delivered peptide protocols; its DHA licensing status is unverified in public registers as of mid-2026, and the DHA facility search tool should be used to confirm any clinic's authorisation before booking. CureCell.ae has similarly appeared in Dubai search results as a compounding pharmacy option; verify the current licence status directly with DHA before proceeding.

Step 4: Tier 3, Verify CoA Before Checkout

For research-grade peptides such as the Retatrutide research peptide, which remains unapproved by the FDA or EMA as of mid-2026, the supplier's batch-specific CoA is the primary quality control mechanism. Request the CoA for the exact lot number you will receive, confirm the issuing laboratory holds ISO 17025 accreditation, and cross-reference the accreditation number against the ILAC MRA signatory database. When the order arrives, check that the vial's lot number matches the CoA document. The same scrutiny applies to products positioned closer to clinical use, such as HD Labs Semaglutide 10 mg.

Step 5: Consider Import Quantity

No publicly available MoHAP or UAE Federal Customs Authority circular sets a precise vial count or AED declared-value threshold for personal-use peptide imports as of mid-2026. What is clear from EDE classification guidance is that consignments resembling commercial quantities, or products carrying therapeutic claims, are more likely to be assessed as medicines requiring prior import authorisation. Ordering in quantities consistent with personal research use reduces, but does not eliminate, the risk of customs scrutiny. JCSG ships to UAE addresses; confirm current dispatch timelines and any documentation requirements directly on the relevant product pages, as shipping policies are not independently verified here.

Step 6: Store Correctly on Receipt

Most reconstituted peptides require refrigeration at 2–8 °C. Lyophilised (freeze-dried) peptides can typically be stored at −20 °C for longer-term stability, though specific conditions vary by compound and manufacturer guidance. Reconstitution supplies including bacteriostatic water and appropriate syringes are available via the peptide accessories section. Incorrect storage after receipt degrades purity regardless of the original CoA result, making post-delivery handling as consequential as supplier selection.

Peptide Supplier Comparison: What to Look for in the UAE (2026)

Six criteria separate a credible UAE peptide supplier from one that creates legal and safety exposure: batch-specific third-party testing, clear regulatory-tier labelling, UAE/GCC dispatch capability, cold-chain packaging, AED-denominated pricing, and GMT+4 customer support. Evaluating a supplier against all six before ordering is the most reliable way to avoid receiving a product that is either adulterated or misclassified under EDE guidance.

The Six-Criteria Checklist

Criterion	What good looks like	Red flags
Certificate of Analysis (CoA)	Batch-specific, issued by an ISO 17025-accredited independent laboratory with the accreditation number visible	Generic "in-house" certificate, no lab name, no accreditation number, or a single CoA applied to multiple batches
Regulatory-tier labelling	Product page explicitly states whether the item is a research peptide, a compounded preparation, or a MoHAP/EDE-registered medicine	No classification statement; therapeutic claims made without prescription context; "supplement" framing applied to prescription-class compounds
UAE/GCC dispatch capability	Confirmed shipping to Dubai, Abu Dhabi, and Sharjah; realistic delivery window stated; customs documentation guidance provided	No UAE shipping confirmation; USD-only checkout with no AED equivalent; no mention of customs handling
Cold-chain packaging	Lyophilised peptides shipped with insulated packaging; temperature-sensitive products include ice packs or dry ice for UAE summer conditions (ambient temperatures regularly exceed 40 °C)	Standard postal packaging with no temperature control; no storage instructions included
Pricing transparency	Prices stated in AED; import duty treatment disclosed or absorbed	USD-only pricing; hidden fees applied at checkout; no clarity on whether UAE VAT (5%) is included
Customer support timezone	Live or responsive support available during UAE business hours (GMT+4, Sunday to Thursday)	Support only available during US or European hours; no Middle East contact option

JCSG's Position Against These Criteria

JCSG supplies pharmaceutical-quality peptides with batch-tested purity and ships to UAE addresses. Product pages include CoA documentation tied to specific lot numbers, which is the minimum the table above identifies as acceptable. For GLP-1 research compounds, the Retatrutide research peptide page reflects the Tier 3 classification appropriate for a pipeline molecule that has not received FDA, EMA, or EDE approval as of mid-2026. For higher-profile compounds such as HD Labs Semaglutide 10 mg, cross-reference the product listing against the lot number on the accompanying CoA before placing any order.

No independently verified DHA licence data is available for other named UAE peptide platforms as of mid-2026; use the DHA facility search tool directly to confirm any clinic or pharmacy's authorisation status rather than relying on supplier self-description.

Peptide Therapy in the UAE: Clinic vs. Self-Research Protocols

Supervised peptide therapy and self-directed research protocols are two legally distinct access routes in the UAE. The route a buyer chooses determines their regulatory exposure, cost structure, and medical safety net before a single vial is ordered.

Supervised Therapy: Tier 1 and Tier 2 Access

Under a supervised model, a DHA- or MoHAP-licensed practitioner prescribes the peptide, a licensed pharmacy or DHA-authorised compounding facility dispenses it, and the patient receives follow-up monitoring. This is the legally unambiguous route for GLP-1 agonists. Semaglutide and tirzepatide are registered prescription medicines under the EDE following Federal Decree-Law No. 38 of 2024, meaning any clinical administration outside a licensed prescriber-pharmacy chain is non-compliant with UAE medicines law. CureCell.ae operates a compounding pharmacy model that sits within this supervised tier for preparations not available as finished registered products.

DarDoc.com's website references "25+ DHA-licensed protocols" as of a 2025–2026 search result snapshot, but that claim is unverified against the DHA public facility register. Query the DHA facility search tool directly using any clinic or platform name before assuming a service is licensed.

Self-Directed Research Protocols: Tier 3 Access

Tier 3 research peptides, compounds with no MoHAP/EDE registration and no DHA-licensed compounding pathway, are sold for laboratory and research purposes only. The buyer assumes full legal and safety responsibility: there is no prescriber oversight, no dispensing pharmacist review, and no structured follow-up. JCSG products, including research-format blends such as the fat-loss blend and glutathione, are sold explicitly under this research-use classification.

For pipeline molecules such as Retatrutide, which has not received FDA, EMA, or EDE approval as of mid-2026, Tier 3 is the only available access route. The cost differential between tiers is real: a supervised GLP-1 protocol through a licensed Dubai clinic typically includes consultation fees, monitoring bloods, and pharmacy dispensing costs that research-format purchasing does not carry. That lower barrier does not alter the legal classification of the compound or the buyer's responsibility under UAE law.

Frequently Asked Questions: Peptides in the UAE